Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADAM metallopeptidase with thrombospondin type 1 motif 14 (ADAMTS14) is a secreted extracellular matrix protease and a member of the ADAMTS family, characterized by a signal peptide, a prodomain, a metalloprotease domain, a disintegrin-like domain, and a thrombospondin-1-like domain. It functions mainly in the processing of the amino-propeptides of fibrillar collagens, enabling collagen fibril formation prior to collagen assembly in the extracellular matrix. ADAMTS14 plays roles in ECM remodeling, cell migration, angiogenesis, and inflammation. Pathologically, it is implicated in osteoarthritis (by contributing to cartilage degradation), intervertebral disc disease, cancer progression (tumor invasion and angiogenesis), cardiovascular remodeling, and neurodegenerative diseases (neuroinflammation and neuronal damage)
Inhibition or modulation of proteolytic activity for prevention of ECM degradation, tumor growth, or inflammation (inferred from disease roles and biological functions since no specific drug listed)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ADAM metallopeptidase with thrombospondin type 1 motif 14 (ADAMTS14).